Studies linked better overall brain health, higher midlife vitamin D levels and lifelong intellectual activity with lower Alzheimer’s-related vulnerability. Findings included lower tau pathology, delayed mild cognitive impairment and dementia onset, and higher cognitive resilience.
Prothena reported Q4 2025 adjusted loss of 45 cents per share, meeting estimates, while ending the year with $308.4 million in cash. Roche and Novo Nordisk advanced partnered programs prasinezumab and coramitug into Phase III trials.
A single blood test measuring p-tau217 protein can predict when cognitively unimpaired individuals will develop Alzheimer's symptoms, with a margin of error of 3-4 years, potentially accelerating clinical trials.
XingImaging will oversee PET imaging operations for the Alzheimer's Tau Platform Phase II trial, a multi-arm study investigating tau-directed therapies in up to 750 participants across 78 U.S. clinical sites, supported by NIH Grant R01AG078457.
